Screener
Bioventus BVS Ratios & Valuation
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 68.7%+1.1pp | 68.7%+1.2pp | 68.3%+0.6pp | 67.8%+0.8pp | 67.6%+1.1pp | |
| Operating margin | 10%— | 10%— | 9.5%— | —— | —— | |
| Net margin | 9.4%+9.5pp | 4.9%+10.9pp | 4%+10.3pp | 1.3%+8.9pp | -0.1%+8.1pp | |
| Returns | ||||||
| Return on equity | 28%+28.4pp | 16.9%+38.1pp | 13.7%+36.2pp | 4.8%+30.5pp | -0.5%+25.9pp | |
| Return on invested capital | 12.2%+8.7pp | 12.3%+18.4pp | 11.9%+18.2pp | 5.2%+9.4pp | 3.5%+7.9pp | |
| Efficiency | ||||||
| Asset turnover | 0.8×+0.1× | 0.9×+0.1× | 0.8×+0.1× | 0.8×+0.1× | 0.8×+0.1× | |
| Liquidity | ||||||
| Current ratio | 1.7×+0.2× | 1.7×+0.3× | 1.7×+0.4× | 1.7×+0.3× | 1.5×+0.1× | |
| Leverage | ||||||
| Debt-to-equity | 1.2×-1.1× | 1.5×-0.9× | 1.7×-0.7× | 2.1×-0.7× | 2.2×-0.5× | |
| Net debt / EBITDA | 2.3×-2.7× | 2.4×-17.0× | 2.6×-15.3× | 4.1×-9.5× | 4.9×-8.9× | |
| Per Share | ||||||
| Book value per share | $3.22+37.0% | $2.70+20.2% | $2.67+16.6% | $2.41+5.9% | $2.35-0.2% | |
| Valuation | ||||||
| Market capitalization | $1.19B+156% | $615.07M+1.6% | $498.3M-27.4% | $447.51M-41.5% | $448.58M+23.1% | |
| Price / earnings | 21.8×— | 21.6×— | 21.9×— | 59×— | —— | |
| Price / sales | 2×+1.2× | 1.1×0.0× | 0.9×-0.3× | 0.8×-0.6× | 0.8×+0.1× | |
| Price / book | 5.2×+2.3× | 3.3×-0.8× | 2.7×-1.9× | 2.7×-2.5× | 2.8×+0.4× | |
| EV / EBITDA | 13.7×+1.8× | 8.4×-45.5× | 7.5×-49.3× | 10.2×-32.0× | 11.7×-15.6× |
FAQ
- What are Bioventus's profit margins?
- Bioventus (BVS) runs a 68.7% gross margin and a 10.0% operating margin, with a 9.4% net margin.
- Where do Bioventus's ratios come from?
- Every ratio is computed from Bioventus's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
